Neuroinflammatory demyelinating diseases, such as Multiple Sclerosis (MS), can lead to significant neurodegeneration, causing debilitating neurological symptoms. Siponimod, a selective sphingosine-1-phosphate receptor modulator, has shown promise in the treatment of MS by modulating immune cell trafficking and reducing neuroinflammation. In this study, we investigated the effect of siponimod on brain and spinal cord imaging markers of neurodegeneration using a murine model of demyelination caused by Theiler's Murine Encephalomyelitis Virus (TMEV). Through comprehensive neuroimaging analysis, we evaluated the impact of siponimod on demyelination-associated neurodegeneration, providing insights into its potential as a therapeutic intervention in demyelinating diseases.
HTML PDFShare this article
Journal of Spine received 2022 citations as per Google Scholar report
